...
首页> 外文期刊>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association >Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy.
【24h】

Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy.

机译:不可切除的胆管癌:比较单纯胆道支架置入术与光动力疗法置入支架的生存率。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND & AIMS: Photodynamic therapy (PDT) for unresectable cholangiocarcinoma is associated with improvement in cholestasis, quality of life, and potentially survival. We compared survival in patients with unresectable cholangiocarcinoma undergoing endoscopic retrograde cholangiopancreatography (ERCP) with PDT and stent placement with a group undergoing ERCP with stent placement alone. METHODS: Forty-eight patients were palliated for unresectable cholangiocarcinoma during a 5-year period. Nineteen were treated with PDT and stents; 29 patients treated with biliary stents alone served as a control group. Multivariate analysis was performed by using Model for End-Stage Liver Disease score, age, treatment by chemotherapy or radiation, and number of ERCP procedures and PDT sessions to detect predictors of survival. RESULTS: Kaplan-Meier analysis demonstrated improved survival in the PDT group compared with the stent only group (16.2 vs 7.4 months, P<.004). Mortality in the PDT group at 3, 6, and 12 months was 0%, 16%, and 56%, respectively. The corresponding mortality in the stent group was 28%, 52%, and 82%, respectively. The difference between the 2 groups was significant at 3 months and 6 months but not at 12 months. Only the number of ERCP procedures and number of PDT sessions were significant on multivariate analysis. Adverse events specific to PDT included 3 patients with skin phototoxicity requiring topical therapy only. CONCLUSIONS: ERCP with PDT seems to increase survival in patients with unresectable cholangiocarcinoma when compared with ERCP alone. It remains to be proved whether this effect is attributable to PDT or the number of ERCP sessions. A prospective randomized multicenter study is required to confirm these data.
机译:背景与目的:不可切除胆管癌的光动力疗法(PDT)与胆汁淤积,生活质量和潜在生存率的改善有关。我们将接受内镜逆行胰胆管造影(ERCP)和PDT和支架置入的不可切除胆管癌患者与仅接受支架置入的ERCP组进行了比较。方法:在5年的时间里,有48例因无法切除的胆管癌而姑息。 PDT和支架治疗了19例;仅采用胆道支架治疗的29例患者作为对照组。通过使用终末期肝病模型评分,年龄,化学疗法或放射治疗以及ERCP程序和PDT疗程次数来检测生存预测因素,进行多变量分析。结果:Kaplan-Meier分析显示,PDT组的生存率比仅支架组提高(16.2 vs 7.4个月,P <.004)。 PDT组在3、6和12个月时的死亡率分别为0%,16%和56%。支架组的相应死亡率分别为28%,52%和82%。两组之间在3个月和6个月时差异显着,但在12个月时没有差异。在多变量分析中,只有ERCP程序的数量和PDT会话的数量才有意义。 PDT的不良事件包括3例仅需局部治疗的皮肤光毒性患者。结论:与单独的ERCP相比,ERCP合并PDT似乎可增加不可切除胆管癌患者的生存率。这种影响是否归因于PDT或ERCP会话数尚待证实。需要进行前瞻性随机多中心研究以确认这些数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号